Biodegradable Polymer Versus Permanent Polymer Drug-Eluting Stents and Everolimus- Versus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease
Authors:
- Robert A. ByrneRBRobert A. Byrne
- Adnan KastratiAKAdnan Kastrati
- Steffen MassbergSMSteffen Massberg
- Anna WieczorekAWAnna Wieczorek
- Karl-Ludwig LaugwitzKLKarl-Ludwig Laugwitz
- Martin HadamitzkyMHMartin Hadamitzky
- Stefanie SchulzSSStefanie Schulz
- Jürgen PacheJPJürgen Pache
- Massimiliano FusaroMFMassimiliano Fusaro
- Jörg HausleiterJHJörg Hausleiter
- Albert SchömigASAlbert Schömig
- Julinda MehilliJMJulinda Mehilli
- 1 September 2011
- Vol. 58 (13) , 1325-1331
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- 2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily PracticeJACC, 2011
- Randomized Comparison of Everolimus- and Paclitaxel-Eluting StentsJACC, 2011
- Drug-Eluting versus Bare-Metal Stents in Large Coronary ArteriesNew England Journal of Medicine, 2010
- Rationale and Design of a Randomized Clinical Comparison of Everolimus-Eluting (Xience V/Promus) and Sirolimus-Eluting (Cypher Select+) Coronary Stents in Unselected Patients with Coronary Heart DiseaseCardiology, 2010
- New drug-eluting stent conceptsNature Reviews Cardiology, 2010
- Drug-Eluting Stents in Percutaneous Coronary InterventionDrug Safety, 2009
- Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) TrialEuropean Heart Journal, 2009
- Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trialThe Lancet, 2008
- Vascular Responses to Drug Eluting StentsArteriosclerosis, Thrombosis, and Vascular Biology, 2007